Literature DB >> 19058972

Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies.

Dawn A Delfín1, Rachel E Morgan, Xiaohua Zhu, Karl A Werbovetz.   

Abstract

BTB 06237 (2-[(2,4-dichloro-5-methylphenyl)sulfanyl]-1,3-dinitro-5-(trifluoromethyl) benzene), a compound previously identified through QSAR pharmacophore development and a virtual screen of the Maybridge database, possesses potent and selective activity against Leishmania parasites. In the present study, several analogs of BTB 06237 were synthesized and analyzed for activity against Leishmania axenic amastigotes, their ability to reduce the level of parasitemia in peritoneal macrophages, and their ability to generate reactive oxygen species (ROS) in L. donovani promastigotes. It was found that an aromatic ring must be present in the position occupied by the 2,4-dichloro-5-methylphenyl group in the lead compound, but changing the functional groups generally has little effect on the antileishmanial potency. Alterations to the 1,3-dinitro-5-(trifluoromethyl)benzene ring have more influence on antiparasitic activity with two aromatic nitro groups and a third electron-withdrawing group being required. This structural requirement corresponds with redox potential, the ability to generate ROS in the parasites, and dissipation of the mitochondrial membrane potential. Finally, we used this collection of data to design a new antileishmanial compound with strong activity in vitro and improved properties as an antileishmanial candidate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19058972     DOI: 10.1016/j.bmc.2008.11.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

1.  Identification of new antileishmanial leads from hits obtained by high-throughput screening.

Authors:  Xiaohua Zhu; Trupti Pandharkar; Karl Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studies.

Authors:  Xiaohua Zhu; Qiang Liu; Sihyung Yang; Toufan Parman; Carol E Green; Jon C Mirsalis; Maria de Nazaré Correia Soeiro; Elen Mello de Souza; Cristiane França da Silva; Denise da Gama Jaen Batista; Chad E Stephens; Moloy Banerjee; Abdelbasset A Farahat; Manoj Munde; W David Wilson; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

3.  Antileishmanial and Cytotoxic Activity of Some Highly Oxidized Abietane Diterpenoids from the Bald Cypress, Taxodium distichum.

Authors:  C Benjamin Naman; Anthony D Gromovsky; Cory M Vela; Joshua N Fletcher; Gaurav Gupta; Sanjay Varikuti; Xiaohua Zhu; Emilia M Zywot; Heebyung Chai; Karl A Werbovetz; Abhay R Satoskar; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2016-02-23       Impact factor: 4.050

4.  Novel arylimidamides for treatment of visceral leishmaniasis.

Authors:  Michael Zhuo Wang; Xiaohua Zhu; Anuradha Srivastava; Qiang Liu; J Mark Sweat; Trupti Pandharkar; Chad E Stephens; Ed Riccio; Toufan Parman; Manoj Munde; Swati Mandal; Rentala Madhubala; Richard R Tidwell; W David Wilson; David W Boykin; James Edwin Hall; Dennis E Kyle; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

5.  SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.

Authors:  Xiaohua Zhu; Kurt S Van Horn; Megan M Barber; Sihyung Yang; Michael Zhuo Wang; Roman Manetsch; Karl A Werbovetz
Journal:  Bioorg Med Chem       Date:  2015-02-18       Impact factor: 3.641

6.  Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies.

Authors:  Catharine J Collar; Xiaohua Zhu; Karl Werbovetz; David W Boykin; W David Wilson
Journal:  Bioorg Med Chem       Date:  2011-06-16       Impact factor: 3.641

7.  Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations.

Authors:  April C Joice; Sihyung Yang; Abdelbasset A Farahat; Heidi Meeds; Mei Feng; Junan Li; David W Boykin; Michael Zhuo Wang; Karl A Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides.

Authors:  Moloy Banerjee; Abdelbasset A Farahat; Arvind Kumar; Tanja Wenzler; Reto Brun; Manoj M Munde; W David Wilson; Xiaohua Zhu; Karl A Werbovetz; David W Boykin
Journal:  Eur J Med Chem       Date:  2012-07-14       Impact factor: 6.514

9.  Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis.

Authors:  Abdolali Malmasi; Bijan Ziaie Ardestani; Mehdi Mohebali; Behnaz Akhoundi; Shadi Ziaie; Majid Masoudifard; Hamidreza Khorram Khorshid; Mehdi Nasiri; Saeed Bayanolhagh; Ehsan Mostafavi; Moin Delrobai; Vahid Siavashi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

10.  Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.

Authors:  Kurt S Van Horn; Xiaohua Zhu; Trupti Pandharkar; Sihyung Yang; Brian Vesely; Manu Vanaerschot; Jean-Claude Dujardin; Suman Rijal; Dennis E Kyle; Michael Zhuo Wang; Karl A Werbovetz; Roman Manetsch
Journal:  J Med Chem       Date:  2014-06-17       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.